Innovative Near-Patient Testing with Rapid Results
Bluejay Diagnostics, Inc. is a late-stage, pre-revenue diagnostics/medical device company focused on improving patient outcomes through the Symphony™ Suite, a cost-effective, rapid, near-patient product candidate for triage and monitoring of disease progression in hospital and long-term acute care (LTAC) settings.
Bluejay’s first product candidate, an IL-6 test for sepsis triage, is designed to provide accurate, reliable results in approximately 20 minutes from ‘sample-to-result’ to help medical professionals make earlier and better triage/treatment decisions.
Publicly traded (NASDAQ: BJDX), Bluejay is expected to apply for FDA approval in 2027.
Mission & Values
Bluejay Diagnostics is dedicated to developing technologies that enhance patient outcomes and enable rapid, accurate testing – delivering actionable insights to clinicians in a fraction of the time.
The goal is to save lives through innovative technologies by helping clinicians make earlier treatment decisions. Bluejay is focused on developing quality products that simplify the diagnostic process. The Symphony Suite is designed to improve patient outcomes while reducing the total cost of care.